Aliskiren/hydrochlorothiazide

Aliskiren/hydrochlorothiazide, sold under the trade name Tekturna HCT among others, is a fixed-dose combination medication for the treatment of hypertension (high blood pressure).[1][2] It contains aliskiren and hydrochlorothiazide.[1][2]

Aliskiren/hydrochlorothiazide
Combination of
AliskirenRenin inhibitor
HydrochlorothiazideDiuretic
Clinical data
Trade namesTekturna HCT, Rasilez HCT, others
AHFS/Drugs.comProfessional Drug Facts
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Aliskiren/hydrochlorothiazide was approved for medical use in the United States in January 2008,[3] and for use in the European Union in January 2009.[2]

References
  1. "Tekturna HCT- aliskiren hemifumarate and hydrochlorothiazide tablet, film coated". DailyMed. 7 January 2020. Retrieved 26 August 2020.
  2. "Rasilez HCT EPAR". European Medicines Agency. Retrieved 27 August 2020.
  3. "Drug Approval Package: Tekturna HCT (aliskiren/hydrochlorothiazide) NDA #022107". accessdata.fda.gov. 24 December 1999. Retrieved 27 August 2020. Lay summary (PDF).


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.